INTERIM FINANCIAL STATEMENTS

Interim Financial Statements 2026

Interim period ended 28 February 2026
Publication date: 15 June 2026
Currency: Euro (EUR)

The interim FY2026 view highlights liquidity and working-capital discipline before later funding events were confirmed.

Key Figures

Metric	Value
Total assets	EUR 7,476.39
Cash and deposits	EUR 258.30
Equity	EUR -1,064.88
Liabilities	EUR 8,541.27
Supplier liabilities	EUR 7,866.32
External services	EUR 1,372.42
Personnel expenses	EUR 2,624.44
Net result	EUR -4,575.68

Management Context

The interim result has not been annualized and does not represent a full-year forecast.

Low cash, negative equity, and supplier liabilities make funding timing, cost discipline, and working-capital control key investor diligence topics.

The reviewed source set does not establish subsequent cash receipts, investor proceeds, customer collections, final EIC payment schedule, or full-year FY2026 forecast.

Evidence Boundary

The reviewed source set does not establish unsupported revenue, customers, investments, valuation, regulatory authorization, or clinical deployment.